Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

drug approval expired 92% Health

Mabwell's antibody drug 9MW5211 for inflammatory bowel disease has received clinical trial clearance from China's National Medical Products Administration, marking a significant advancement in biopharmaceutical innovation.

🇨🇳 Location: Shanghai — Sources: 2 — First seen: — Last seen:
Mabwell clinical trials inflammatory bowel disease NMPA biopharmaceuticals

Linked Entities

Mabwell

organization involved

NMPA

organization involved

Shanghai

location involved 🇨🇳

Vcare PharmaTech

organization involved

Nanjing

location involved 🇨🇳

Contributing Articles